Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics

Drug Profile

Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics

Alternative Names: INT 223-8; INT 230-6

Latest Information Update: 08 Jun 2016

Price : $50

At a glance

  • Originator Intensity Therapeutics
  • Developer Intensity Therapeutics; National Cancer Institute (USA)
  • Class Cancer vaccines; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Immunostimulants; Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jun 2016 Intensity Therapeutics has patent protection for INT 230-6 in USA
  • 19 Apr 2016 Preclinical data presented at the American Academy of Cancer Research (AACR-2016)
  • 16 Apr 2016 Interim pharmacodynamics data from a preclinical trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top